Francesco Calzaferri was a recent Postdoctoral Researcher in the group of Prof. Silvia Giordani at Dublin City University, supported by her Research Ireland Frontiers for the Future Programme Award (2/FFP-A/11067).

Francesco received his PhD in Pharmacology and Physiology from the Universidad Autónoma de Madrid in 2021, where he developed a novel brain-permeable antagonist of the P2X7 receptor to address neurodegenerative and neuroinflammatory disorders. He subsequently held a postdoctoral fellowship funded by the ARC Foundation in Montpellier, focusing on the discovery and optimization of bioactive molecules targeting DNA and histone methyltransferases—key epigenetic regulators implicated in cancer development and progression. He joined the Giordani Group in March 2025, and his research focused on the design, synthesis, and biological evaluation of smart nanoparticles for spatio-temporally controlled drug release in cancer therapy.